Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation

Oncogene

Volumn 28, Issue 11, 2009, Pages 1443-1453

  Greenow, K R ^a   Clarke, A R ^a   Jones, R H ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Apoptosis; Chk1; DNA damage; p53; Small intestine

Indexed keywords

ATM PROTEIN; CHECKPOINT KINASE 1; HISTONE H2AX; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; INTESTINE CRYPT; LETHALITY; LIVER; LOXP SITE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE; TUMOR CELL;

ANIMALS; APOPTOSIS; BETA-NAPHTHOFLAVONE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; HISTONES; INTESTINE, SMALL; MICE; PHOSPHORYLATION; PROTEIN KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 62649115931     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.482     Document Type: Article

References (29)

1. Bakkenist CJ, Kastan MB. (2003). DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421: 499-506.
2. Bartek J, Lukas J. (2003). Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3: 421-429.
3. Bjerknes M, Cheng H. (1981). Methods for the isolation of intact epithelium from the mouse intestine. Anat Rec 199: 565-574.
4. Chen Z, Xiao Z, Chen J, Ng SC, Sowin T, Sham H et al. (2003). Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint. Mol Cancer Ther 2: 543-548.
5. Hapke G, Yin MB, Rustum YM. (2001). Targeting molecular signals in chk1 pathways as a new approach for overcoming drug resistance. Cancer Metastasis Rev 20: 109-115.
6. Ireland H, Kemp R, Houghton C, Howard L, Clarke AR, Sansom OJ et al. (2004). Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of beta-catenin. Gastroenterology 126: 1236-1246.
7. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. (2001). Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29: 418-425.
8. Kawabe T. (2004). G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3: 513-519.
9. Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O'Connell MJ. (2001). Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20: 7453-7463.
10. Kramer A, Mailand N, Lukas C, Syljuasen RG, Wilkinson CJ, Nigg EA et al. (2004). Centrosome-associated Chk1 prevents premature activation of cyclin-B-Cdk1 kinase. Nat Cell Biol 6: 884-891.
11. Lam MH, Liu Q, Elledge SJ, Rosen JM. (2004). Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 6: 45-59.
12. Levine AJ. (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
13. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K et al. (2000). Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Genes Dev 14: 1448-1459.
14. Merritt AJ, Allen TD, Potten CS, Hickman JA. (1997). Apoptosis in small intestinal epithelial from p53-null mice: evidence for a delayed, p53-independent G2/M-associated cell death after gamma-irradiation. Oncogene 14: 2759-2766.
15. Nyberg KA, Michelson RJ, Putnam CW, Weinert TA. (2002). Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 36: 617-656.
16. Robinson HM, Jones R, Walker M, Zachos G, Brown R, Cassidy J et al. (2006). Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 25: 5359-5369.
17. Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM. (2000). Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 275: 9390-9395.
18. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. (1998). DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273: 5858-5868.
19. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. (2004). Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39-85.
20. Sansom OJ, Griffiths DF, Reed KR, Winton DJ, Clarke AR. (2005). Apc deficiency predisposes to renal carcinoma in the mouse. Oncogene 24: 8205-8210.
21. Shibata H, Toyama K, Shioya H, Ito M, Hirota M, Hasegawa S et al. (1997). Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278: 120-123.
22. Soriano P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21: 70-71.
23. Syljuasen RG, Sorensen CS, Hansen LT, Fugger K, Lundin C, Johansson F et al. (2005). Inhibit ion of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol 25: 3553-3562.
24. Takai H, Tominaga K, Motoyama N, Minamishima YA, Nagahama H, Tsukiyama T et al. (2000). Aberrant cell cycle checkpoint function and early embryonic death in Chk1(-/-) mice. Genes Dev 14: 1439-1447.
25. Tse AN, Carvajal R, Schwartz GK. (2007). Targeting checkpoint kinase 1 in cancer therapeutics. Clin Cancer Res 13: 1955-1960.
26. Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. (1996). UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 88: 956-965.
27. Xiao Z, Chen Z, Gunasekera AH, Sowin TJ, Rosenberg SH, Fesik S et al. (2003). Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents. J Biol Chem 278: 21767-21773.
28. Zachos G, Rainey MD, Gillespie DA. (2003). Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J 22: 713-723.
29. Zaugg K, Su YW, Reilly PT, Moolani Y, Cheung CC, Hakem R et al. (2007). Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. Proc Natl Acad Sci USA 104: 3805-3810.